Your browser doesn't support javascript.
loading
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
Sankaranarayanan, Rengaswamy; Prabhu, Priya Ramesh; Pawlita, Michael; Gheit, Tarik; Bhatla, Neerja; Muwonge, Richard; Nene, Bhagwan M; Esmy, Pulikottil Okuru; Joshi, Smita; Poli, Usha Rani Reddy; Jivarajani, Parimal; Verma, Yogesh; Zomawia, Eric; Siddiqi, Maqsood; Shastri, Surendra S; Jayant, Kasturi; Malvi, Sylla G; Lucas, Eric; Michel, Angelika; Butt, Julia; Vijayamma, Janki Mohan Babu; Sankaran, Subha; Kannan, Thiraviam Pillai Rameshwari Ammal; Varghese, Rintu; Divate, Uma; Thomas, Shila; Joshi, Geeta; Willhauck-Fleckenstein, Martina; Waterboer, Tim; Müller, Martin; Sehr, Peter; Hingmire, Sanjay; Kriplani, Alka; Mishra, Gauravi; Pimple, Sharmila; Jadhav, Radhika; Sauvaget, Catherine; Tommasino, Massimo; Pillai, Madhavan Radhakrishna.
Afiliación
  • Sankaranarayanan R; Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France. Electronic address: sankarr@iarc.fr.
  • Prabhu PR; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
  • Pawlita M; Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Gheit T; Infections and Cancer Biology Group, Infections Section, International Agency for Research on Cancer, Lyon, France.
  • Bhatla N; Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  • Muwonge R; Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
  • Nene BM; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
  • Esmy PO; Christian Fellowship Community Health Centre, Ambillikai, Tamil Nadu, India.
  • Joshi S; Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
  • Poli UR; Mehdi Nawaj Jung Institute of Oncology and Regional Cancer Center, Red Hills, Lakadikapul, Hyderabad, Andhra Pradesh, India.
  • Jivarajani P; Health Care Global Cancer Centre, Sola-Science City Road, Near Sola Bridge, Ahmedabad, Gujarat, India.
  • Verma Y; Sir Thodup Namgyal Memorial Hospital/Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India.
  • Zomawia E; Civil Hospital, Aizawl, Mizoram, India.
  • Siddiqi M; Cancer Foundation of India, Kolkata, West Bengal, India.
  • Shastri SS; Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
  • Jayant K; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
  • Malvi SG; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
  • Lucas E; Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
  • Michel A; Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Butt J; Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Vijayamma JM; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
  • Sankaran S; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
  • Kannan TP; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
  • Varghese R; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
  • Divate U; Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
  • Thomas S; Christian Fellowship Community Health Centre, Ambillikai, Tamil Nadu, India.
  • Joshi G; Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Civil Hospital Campus, Asarwa, Ahmedabad, India.
  • Willhauck-Fleckenstein M; Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Waterboer T; Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Müller M; Tumorvirus-specific Vaccination Strategies, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
  • Sehr P; EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Hingmire S; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
  • Kriplani A; Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  • Mishra G; Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
  • Pimple S; Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
  • Jadhav R; Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
  • Sauvaget C; Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
  • Tommasino M; Infections and Cancer Biology Group, Infections Section, International Agency for Research on Cancer, Lyon, France.
  • Pillai MR; Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
Lancet Oncol ; 17(1): 67-77, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26652797
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Potencia de la Vacuna / Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Potencia de la Vacuna / Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido